Navigation Links
Engineer to launch bacteria into space aboard the final mission of Space Shuttle Atlantis
Date:6/27/2011

Troy, N.Y. There will be some very interesting passengers on the final mission of the NASA Space Shuttle Atlantis scheduled to launch July 8, 2011: thousands of bacteria.

Cynthia Collins, assistant professor of chemical and biological engineering at Rensselaer, is leading a series of experiments called Micro-2A that will be aboard the shuttle during its scheduled 12-day mission. The research seeks to understand how microgravity changes the way potentially dangerous bacteria grows. In particular, the research will examine how they form difficult-to-kill colonies called biofilms. The research has important implications for protecting astronauts while they are in space in enclosed and difficult-to-clean spaces, such as the International Space Station, or during extended space missions deeper into our solar system. It also provides new information in the fight against ever-more virulent bacterial infections such as staph, food poisoning, sepsis, and pneumonia.

Partnering with Collins on the project are nanobiotechnology expert Jonathan Dordick, the Howard P. Isermann Professor of Chemical and Biological Engineering at Rensselaer and director of the Rensselaer Center for Biotechnology and Interdisciplinary Studies, and thin films expert Joel Plawsky, professor in the Department of Chemical and Biological Engineering. The NASA Ames Research Center is funding the experiment.

This is the second time that Collins' research will be included on the shuttle. Her research on bacteria was also aboard the shuttle mission that launched May 14, 2010. Collins has been analyzing the results of this previous work and will use this new series of experiments to test some of the results she has seen.

"We are clearly seeing altered biofilm formation during space flight," she said. "There are some clear differences between the amount of biofilm formed in normal gravity and microgravity. These differences also appear to be organism dependent, with different organisms responding very differently to the environment in space."

The bacteria that Collins will include are Pseudomonas aeruginosa and Staphylococcus aureus. These bacteria are responsible for more hospital-acquired infections than any other, according to Collins. The Center for Disease Control places hospital-acquired infections such as those caused by these bacteria as the fourth leading cause of death in the United States.

Biofilms are complex, three-dimensional microbial communities. Most biofilms, including those found in the human body, are harmless. Some biofilms, however, have been shown to be associated with disease. Researchers like Collins are discovering that the bacteria within these colonies have very different properties, including increased resistance to antimicrobials, compared with bacteria not encased in a biofilm.

Collins and her team will send up 16 devices, called Group Activation Packs (GAPs) and each containing eight vials of bacteria, aboard the shuttle. The GAPs and other hardware used by the Collins and her team were developed by BioServe Space Technologies. While in orbit, astronauts will begin the experiment by manipulating the sealed GAPs and combining the bacteria with nutrients and a surface on which they can form biofilms. At the same time, Collins will perform the same actions with identical GAPs on Earth at the Kennedy Space Center in Florida. After the shuttle returns, her team will compare the resulting biofilms to see how the behavior of bacteria and development of biofilms in microgravity differs from the Earth-bound control group.

In addition, the research team will also test if a newly developed, antimicrobial surface developed by Dordick at Rensselaer can help slow the growth of methicillin resistant Staphylococcus aureus, or MRSA, on Earth and in microgravity. Actual MRSA, the bacteria responsible for antibiotic-resistant infections, will not be used for the safety of those on board. A different and safer strain of bacteria with similar properties will serve as a proxy. The new surface developed by Dordick utilizes an enzyme found in nature and kills 100 percent of MRSA within 20 minutes of contact.

The new technology marries carbon nanotubes with lysostaphin, a naturally occurring enzyme used by non-pathogenic strains of staph bacteria to defend against staph growth. The resulting nanotube-enzyme biomaterial can be mixed with any number of surface finishes. In tests, it was mixed with ordinary latex house paint. More information on the surface can be found at: http://news.rpi.edu/update.do?artcenterkey=2759.

Astronauts have been shown to have an increased susceptibility to infection while in microgravity, making a deeper understanding of how these bacteria behave in space of particular importance, according to Collins. In addition to its importance in planning future space missions, the research also has important applications here on Earth. The conditions in space are similar to those produced within the human body on several levels. Understanding how bacteria thrive in space may also provide insight into how they develop once they enter the human body.


'/>"/>

Contact: Gabrielle DeMarco
demarg@rpi.edu
518-276-6542
Rensselaer Polytechnic Institute
Source:Eurekalert  

Related biology news :

1. Engineering blue-hued flowers
2. UA engineering college lands national support for equipment used in unique research
3. U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering"
4. Progress in tissue engineering to repair joint damage in osteoarthritis
5. Environmental engineering students and faculty study Passaic River pollution
6. Engineering new weapons in the fight against juvenile diabetes
7. Engineered liver may shed light on effects of chemicals in the environment
8. Columbia Engineering team makes major step in improving forecasts of weather extremes
9. Virginia Tech mechanical engineers win measurement science best paper award
10. Penn researchers help nanoscale engineers choose self-assembling proteins
11. Stevens biomedical engineering students fight hypothermia on the battlefield
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Engineer to launch bacteria into space aboard the final mission of Space Shuttle Atlantis
(Date:2/2/2016)... 2, 2016   Parabon NanoLabs (Parabon) ... Army Research Office and the Defense Forensics and ... of the company,s Snapshot Kinship Inference ... more generally, defense-related DNA forensics.  Although Snapshot is ... appearance and ancestry from DNA evidence), it also ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/27/2016)... Jan. 27, 2016  Rite Track, Inc. a leading ... West Chester, Ohio announced today the ... staff, based in Austin, Texas , ... to provide modifications, installations and technical support offerings for ... of PLUS, commented, "PLUS has provided world class service ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... -- On Thursday, February 11, 2-1-1 San Diego ... and disaster services, and the Community Information Exchange ... coordination and service delivery for the community to better ... better connect service providers to the information they can ... has handled more than 2.5 million connections ...
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
(Date:2/4/2016)... 4, 2016 Beike Biotechnology, the ... attended a ceremony in late 2015 to mark their ... in 2016. --> --> ... for Personalized Cell Therapy" was hosted by the Shenzhen ... both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
Breaking Biology Technology: